Tumour necrosis factor antagonists and inflammatory bowel diseases: a national practice survey |
| |
Authors: | A. OUSSALAH,X. ROBLIN&dagger ,D. LAHARIE&Dagger ,J. FILIPPI§ ,M. FLAMANT¶ ,P. FAURE,J.-M. PHELIP&dagger ,M.-A. BIGARD,& L. PEYRIN-BIROULET |
| |
Affiliation: | Inserm, U954 and Department of Hepato-Gastroenterology, University Hospital of Nancy, Vandoeuvre-lès-Nancy, France;;Department of Hepato-Gastroenterology, University Hospital of Saint-Etienne, Saint-Etienne, France;;Gastroenterology and Hepatology Unit, Haut-Lévêque hospital, Pessac, France;;Department of Gastroenterology and Clinical nutrition, University Hospital of Nice, Archet 2 hospital, Nice, France;;Department of Hepato-Gastroenterology, Digestive diseases institute, University Hospital of Nantes, Nantes, France;;Saint Jean Languedoc Clinic, Toulouse, France |
| |
Abstract: | Background Although the use of tumour necrosis factor (TNF) antagonists is increasingly codified, several unresolved issues remain. Aim To conduct a French national survey on TNF antagonists use in inflammatory bowel disease (IBD). Methods A postal questionnaire was sent to all French gastroenterologists among whom 450 prescribe TNF antagonists for IBD. Only anti-TNF prescribers were invited to respond. Results A total of 333 questionnaires could be analysed, which represented a rate of survey completeness of 74%. Scheduled maintenance infliximab treatment was prescribed by 92% of gastroenterologists. In Crohn's disease in remission after 1 year of TNF antagonists, 77.4% of physicians continued treatment. In luminal Crohn's disease, 97% of hospital practitioners introduced infliximab as first-line anti-TNF therapy vs. 78% of physicians with nonhospital activity ( P = 0.002); only 22.5% of gastroenterologists opted for adalimumab as first-line therapy. In Crohn's disease in remission after 6 months of azathioprine in combination with infliximab, 63.8% of practitioners discontinued azathioprine. In case of pregnancy during anti-TNF treatment, 35.1% of physicians discontinued therapy at the time of conception and did not administer anti-TNF therapy during pregnancy. Conclusions The attitudes of French gastroenterologists generally reflect the recommendations regarding the use of anti-TNF and concomitant immunosuppressive therapy in IBD. |
| |
Keywords: | |
|
|